| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8736418 | Autoimmunity Reviews | 2018 | 32 Pages |
Abstract
This review confirms that TCZ is safe and effective in refractory cases of TA and TCZ is a corticosteroid-sparing therapy in patients with or without previous TNFα blockers therapy. However relapses after TCZ discontinuation are frequent.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Paul Decker, Pierre Olivier, Jessie Risse, Stéphane Zuily, Denis Wahl,